Tetra Bio-Pharma, Targeted Pharmaceutical & the George Mason University Partner on ARDS-003 to Prevent & Treat COVID-19
Tetra Bio-Pharma has entered a research collaboration with Targeted Pharmaceutical and George Mason University's NCBID to evaluate ARDS-003 in SARS-CoV-2 infected animals. This partnership aims to explore ARDS-003's potential as a therapeutic agent against COVID-19. Tetra has obtained a 20% minority stake in Targeted Pharmaceutical, enhancing its research capabilities. The project will be led by Dr. Lance Liotta, providing significant insights into the drug's role in modulating cytokine release during COVID-19 infection.
- Collaboration with George Mason University's NCBID enhances research capabilities.
- Evaluation of ARDS-003 could provide insights into COVID-19 treatment.
- Acquisition of a 20% minority stake in Targeted Pharmaceutical strengthens partnerships.
- No expressed claims about ARDS-003's effectiveness against COVID-19.
- Dependency on animal trials for validation of ARDS-003's therapeutic potential.
- Tetra, Targeted Pharmaceutical and the George Mason University National Center for Biodefense and Infectious Diseases (NCBID) sign a research collaboration
- ARDS-003 to be evaluated in Sars-CoV-2 infected animals at the Biocontainment Laboratory-George Mason University NCBID
OTTAWA, ON / ACCESSWIRE / October 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is excited to announce that it has signed a research collaboration agreement with Targeted Pharmaceutical and the George Mason University NCBID. As previously disclosed last quarter, Tetra officially acquired a
The NCBID is a leading institute conducting pioneering research on infectious diseases including diagnostic, therapeutics, and vaccine development. The research collaboration will allow the evaluation of ARDS-003, with and without antiviral drugs, to prevent and treat SARS-CoV-2 infection in animals.
Under the leadership of Dr. Lance Liotta, Chief Medical Officer at Targeted Therapeutics, and Professor at the George Mason University, ARDS-003 will be studied in SARS-CoV-2 infected animals to further understand its potential as a preventive and therapeutic medicine. This research will be performed by Dr. Liotta's team at the Biocontainment Laboratory-George Mason University NCBID. Dr. Liotta has served as Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at the George Mason University. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology, NCI, Deputy Director of NIH, Co-Director of the NCI/FDA Clinical Proteomics Program, and Director of the Anatomic Pathology Residency Program.
Dr. Guy Chamberland, CEO and CRO commented, "We have initiated this research agreement to generate new intellectual property and work closer with key researchers in the USA who are investigating therapeutic agents for treatment of patients who are severely ill from COVID-19. Teaming up with Targeted Pharmaceutical opened the door to a collaboration with a prestigious USA research laboratory at the George Mason University. Having the ability to study investigational new drugs in animals who are infected with the COVID-19 virus is a major opportunity for us. The research team will gain tremendous knowledge on the role a cytokine release modulating drug plays in COVID-19 infections. This type of animal research was used to study potential drug candidates for Middle East Respiratory Syndrome (MERS-CoV) and most recently the REGN-COV2 antibody in SARS-CoV-2 infected animals. The Company is not making any expressed or implied claims that its product has the ability to eliminate, cure and/or contain the COVID-19 or the SARS-COV-2 virus at this time. "
About George Mason University
George Mason University is Virginia's largest public research university. Located near Washington, D.C., Mason enrolls more than 37,000 students from 130 countries and all 50 states. The National Center for Biodefense and Infectious Diseases (NCBID) at Mason focuses on host-pathogen interactions using proteomics and nanotechnology as they are applied to diagnostic, therapeutic, and vaccine development. NCBID manages The Biomedical Research Lab (BRL), one of thirteen Regional Biocontainment Laboratories in the U.S. constructed with funding support from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), performing pioneering research of infectious diseases, both emerging and potential bio threat agents. Learn more at www.ncbid.gmu.edu
The College of Science at Mason is a leader in scientific discovery creating innovative solutions for the rapidly changing needs of today's world. Mason's College of Science blends traditional science education with sought-after programs in disciplines as diverse as personalized medicine, infectious diseases, geoinformatics, climate dynamics, materials science, astronomy, forensic science, and applied mathematics. The College encourages meaningful education and research at all levels offering innovative undergraduate programs, minors, certificates, and graduate degree opportunities, as well as global, transfer-focused, and online, or hybrid, programs that allow professionals the opportunity to reskill or change careers. Learn more at www.science.gmu.edu
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF), is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a FDA and a Health Canada approved clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies. For more information visit: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.:
Investor Contact:
Tetra Bio-Pharma Inc
Dr. Guy Chamberland, M.Sc., Ph.D.
Chief Executive Officer
Phone: + 1 (833) 977-7575
investors@tetrabiopharma.com
Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net
Media Contact:
energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com
SOURCE: Tetra Bio-Pharma
View source version on accesswire.com:
https://www.accesswire.com/611652/Tetra-Bio-Pharma-Targeted-Pharmaceutical-the-George-Mason-University-Partner-on-ARDS-003-to-Prevent-Treat-COVID-19
FAQ
What is the purpose of the collaboration between Tetra Bio-Pharma and George Mason University?
What role does Dr. Lance Liotta have in the Tetra Bio-Pharma research initiative?
What is ARDS-003 being tested for?
When was the collaboration between Tetra Bio-Pharma and Targeted Pharmaceutical announced?
